News

Charities can fund businesses, says Wellcome Trust officer

There are a growing number of instances where charitable organisations can provide money to profit-making companies and still demonstrate that they are working in the public interest, according Richard Seabrook, head of business development at the Wellcome Trust.

AMT's IPO sells well

Amsterdam Molecular Therapeutics AMT Holding NV, which develops gene-based therapies for orphan diseases, raised €50 million in an initial public offering on the Euronext Amsterdam stock exchange.

Swedish biotech pipeline getting bigger

Swedish biotech companies increased their pipeline of drug candidates substantially in 2007 compared with a year earlier, according to a survey conducted by SwedenBio, an industry association, and two government agencies, Invest in Sweden Agency (ISA) and Vinnova.

EMEA guideline on first-in-man trials due out in July

A guideline outlining how companies should prepare to conduct first-in-man studies of novel medicinal products in Europe, should be completed in July, 2007, according to Patrick Le Courtois, head of the Unit for Pre-Authorisation of Medicines for Human Use at the European Medicines Agency (EMEA).

Santaris presents data on new RNA antagonist

Santaris Pharma A/S of Denmark announced at the June 2007 annual meeting of the American Society of Clinical Oncology in Chicago that its RNA antagonist for chronic lymphocytic leukaemia (CLL) showed promising results in an initial Phase I/II clinical trial.

Biotech CEOs take AIM and smile

Light regulation, low cost and flexible admission criteria make the London Stock Exchange’s Alternative Investment Market (AIM) an attractive venue for small companies that want to issue shares for the first time, according to the chief executive officers of four life science companies that have issued IPOs on AIM since 2004.

European biotech revenues up 13% in 2006

The European biotechnology industry increased its revenues by 13% in 2006, while narrowing its losses. At the same time, spending on research and development increased, especially on the part of the 32 companies that made initial public offerings during the year.